Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2018

View Archived Issues

Phase IIb trial of Mtb72F-AS02A vaccine shows 54% protection against active pulmonary tuberculosis

Let sleeping cells lie: Neutrophil extracellular traps untrap dormant tumor cells

C1QBP found to predict survival in mesothelioma patients under chemotherapy

Immunologically humanized mouse model better captures immune responses during hepatitis B infection

Phase II results presented for ustekinumab in patients with active systemic lupus erythematosus

PFKFB3 inhibitor selectively radiosensitizes cancer cells, blocking homologous recombination

Fluorescent virus-guided cytology detects active cancer cells in peritoneally disseminated GC

Nimbus Lakshmi patents TYK2 inhibitors

In situ TLR9-agonist vaccine plus low dose radiation induces systemic responses in indolent lymphoma

Takeda Pharmaceutical divulges new orexin OX2 receptor agonists

Janssen identifies new BACE inhibitors

Acquired resistance to enasidenib is mediated by a second-site mutation in the IDH2 dimer-interface

U.S. researchers divulge MALT1 inhibitors

Celyad enters agreement to use Horizon Discovery's shRNA technology

New triple-combination study explores plinabulin, nivolumab and ipilimumab in SCLC

Celgene opens recruitment in phase III study of JCAR-017 for second-line NHL

First patient enrolled in phase III study of glepaglutide for short bowel syndrome

Novartis initiates first-in-human study of CPK-850 for retinitis pigmentosa

Phase II data presented from NADIM study of neoadjuvant chemotherapy and immunotherapy in NSCLC

FDA approves Hemlibra for prophylaxis in hemophilia A without factor VIII inhibitors

Alnylam reports phase I/II data on lumasiran in PH1, initiates phase III trial

NIH research grant to support phase II program with PTI-125 in Alzheimer's

Oncology Venture cleared to include prostate cancer patients in phase II study of LiPlaCis

Oramed initiates pilot study of ORMD-0801 in NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...